Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.15 -3.49% 4.15 530,645 16:15:32
Bid Price Offer Price High Price Low Price Open Price
3.80 4.50 4.30 3.75 4.30
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.23 -3.40 -0.73 16
Last Trade Time Trade Type Trade Size Trade Price Currency
16:14:46 O 4,000 3.9544 GBX

Eden Research (EDEN) Latest News

More Eden Research News
Eden Research Investors    Eden Research Takeover Rumours

Eden Research (EDEN) Discussions and Chat

Eden Research Forums and Chat

Date Time Title Posts
25/6/202207:28Eden Research12,392
31/3/202214:47Eden....Onward and Upwards!50
29/3/202216:04Eden Research14
29/3/202214:36Eden Research - Who Is Behind Thallo Eco Products Corp?27
29/3/202214:35Plus Market3

Add a New Thread

Eden Research (EDEN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Eden Research trades in real-time

Eden Research (EDEN) Top Chat Posts

DateSubject
25/6/2022
09:20
Eden Research Daily Update: Eden Research Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 4.30p.
Eden Research Plc has a 4 week average price of 3.75p and a 12 week average price of 3.75p.
The 1 year high share price is 11.75p while the 1 year low share price is currently 3.75p.
There are currently 380,340,229 shares in issue and the average daily traded volume is 382,375 shares. The market capitalisation of Eden Research Plc is £15,784,119.50.
24/6/2022
20:50
neutralpov: NeutraIPOV 24 Jun '22 - 16:27 - 12384 > The usual EDEN is doomed posts from the same usual nut jobs and non holders… erinvale1 24 Jun '22 - 16:31 - 12385 > I recall you repeating that Eden is headed to zero pence. You are uttering the usual unhelpful and uninformative nonsense. @ erinvale1 You have been hoodwinked by one of the bushed/hawthorny ramping team, who forges my username. My username has a lower-case "L" as its 7th character. The forger's one has an upper-case "i" there instead. Spotted it? That's how low these crooks play ... a counterfeiter and fake. RENEWED TARGET share price FOR EDEN.L ZERO PENCE (0.0000 p)
17/6/2022
15:40
investingisatrickygame: Cenkos Report 2022 Page 6, available for anyone to read. Link on Eden's website. A £197 million per annum future opportunity based on proven and developed/developing products. Eden Research market opportunities We analyse the potential for Eden Research’s currently marketed and pipeline opportunities in more detail in this report, providing an overview of the market potential below. In aggregate, we believe Eden Research is targeting significant market opportunities, which could transform the company in the near- to mid-term.  Mevalone – Grapes in the Southern EU zone. Assuming a market share of 10%, we estimate this opportunity could be worth c£10m to Eden Research.  Mevalone – Apples/grapes in the Central EU zone. Assuming a market share of 10%, we estimate this opportunity could also be worth c£10m to Eden Research.  Cedroz – We estimate the potential revenues for Cedroz to treat nematodes in the markets covered by the Eastman Chemicals could be c£24m assuming a 10% market share.  Insecticide – Combining the US and European markets, we estimate the insecticide opportunity could be worth c£58m assuming a 10% market share.  Seed treatment – Eden Research’s seed treatment development with Corteva has the potential to generate c€40m of sales to the company per year.  Sustaine opportunities – Eden Research estimate that the two lead development projects for Sustaine could generate a combined c£60m per year revenue opportunity.
16/6/2022
23:06
neutralpov: ravenna23 16 Jun '22 - 13:24 - 12255 wrote to the Troll: You don’t hold You work for a boiler room or Hawthorn PR The Eden price has fallen 80% in the past year Where am I wrong? I am warning the public off this share Why are you here as a pale imitation of another? BIG FRAUD ========= You asked "Where am I wrong?" It actually fell 81-82% since last February. Not 80% in the last 12 months. And the forger and Identity Thief is merely a troll, not a paid ramper. Otherwise, correct.
16/6/2022
14:19
ravenna23: The Eden price has fallen 80% in the past year. FACTThe Corteva deal is a bust and has not produced any significant sales FACT
16/6/2022
13:24
ravenna23: You don't holdYou work for a boiler room or Hawthorn PRThe Eden price has fallen 80% in the past yearWhere am I wrong?I am warning the public off this shareWhy are you here as a pale imitation of another?BIG FRAUD
02/6/2022
16:11
neutralpov: Good grief, you are crazy. These have no possible bearing on EDEN share price and prospects. Suggest you go back to Melinda Gates's cycle - that has more relevance. :D
31/5/2022
12:42
neutralpov: NORTHWICK 31 May '22 - 12:09 - 12078 > So you know, independent auditors approved the accounts on 30/5/2022. hope [it] helps i.e. yesterday. Just in time for the filing deadline. What relevance does your informational snippet have, aside from that? Accepting the accounts as gospel, T&F etc., don't you see why the share price immediately reacted as it did? Bad was ALREADY expected and factored in. What just landed was even more appalling. Got it? The SM is a futures market. The futures market is a futures futures market. Until you understand that fully, you shouldn't be here, except as a spectator and student Does your wife or wives know how much you've lost so far? ---- Factoid: Grant Thornton audit both EDEN.L and EDEN District Council. A coincidence. Hope they don't get the two sets muddled. 0:-)
27/5/2022
13:52
neutralpov: Ignore the sadistic troll (and forger and crook) above. He has no skin in this game. --- Look at the spectacle of the share price chart. Another few ticks downwards as the shares dumped by Amati are starting to worry the middlemen... today's transactions indicate that one can BUY almost any number at 4.69 pence... yes, BUY. So how the midmarket share price shown here can be 4.75p is a little mystery. And try to sell anything more than a few thousand... hahahaha.... 4p. And a significant number, who knows. 2p? 1p? 0.1p? RESTATED TARGET share price ..... ZERO PENCE (0.000 pence) Ignore the sadistic troll, the madwoman, the paid ramper. Their opinions do not count. Face reality before it smacks you in the face less than five weeks from today. On 9 June, IIRC, we are due another list of significant shareholdings. :) That should provide a lot of entertainment, specially re the ijjit PI.
20/5/2022
12:48
supersonico: 2017 was the time line prediction that JakNife (aka the guy who could not say Cedroz) prematurely made on EDEN's demise. I would happily show you his post but he went all sheepish on Eden and deleted all his posts which is odd for a person with such conviction. You suggest 'Next couple of years' Next couple of years ? and not soon after accounts get published after the FRC intervene and investors including II's who have already witnessed FRC commentary get wind of something more concerning than already has been disclosed by the company that you keep alluding to? 'Next couple of years' bring us to 2024. 2024 is when the Corteva deal is planned to kick off so even a further fund raise and dilution may well be countered and the share price supported by the run up to or the roll out of the biggest deal Eden has announced to date.. and what they have stated so far only includes Europe so we still await a rest of the world / regional announcements which I assume Corteva will be keen to pursue once this first round of the process is concluded. Also don't forget the US Cedroz approvals of Mev and Ced which will have a positive impact on the share price in between times I imagine. While I appreciate your reply the picture you imagine Sounds like an unlikely scenario to me.
18/5/2022
14:45
supersonico: NUMBER OF AIM SECURITIES IN ISSUE As of 09 March 2022, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Atul Unadkat 17,350,145 4.38% Rathbone Nominees Limited 16,095,276 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ..................................... NUMBER OF AIM SECURITIES IN ISSUE As of 18 August 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Rathbone Nominees Limited 16,122,338 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ................... Home SECURITIES INFORMATION NUMBER OF AIM SECURITIES IN ISSUE As of 21 February 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,452,709 6.69% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,421,575 5.37% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,156,166 4.25% Interactive Investor 15,405,978 4.05% HSBC Global Custody Nominee (UK) Limited 14,015,588 3.69% NUMBER OF AIM SECURITIES IN ISSUE As of 21 August 2020, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were: BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Hargreaves Lansdown 30,276,493 7.96% Gresham House Asset Management Limited 27,845,445 7.32% Canaccord Genuity Group Inc 22,684,000 5.94% JM Finn Nominees Limited 21,774,435 5.72% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,246,373 4.27% HSBC Global Custody Nominee (UK) Limited 14,007,734 3.68% Interactive Investor 12,992,073 3.42% hTTps://www.edenresearch.com/investors/securities_information.aspx
Eden Research share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220625 20:01:27